Chair-bound Exergaming in Pre-frail/ Frail Older Adults in Nursing Home

Effectiveness of Chair-bound Exergaming on Physical and Cognitive Functions in Pre-frail/ Frail Older Adults in Nursing Home: A Pilot Randomized Controlled Trial

This pilot randomized controlled trial is designed to investigate the effectiveness of chair-bound exergaming on improving physical and cognitive function in pre-frail/ frail nursing home residents

Study Overview

• Status: Recruiting
• Conditions: Frailty in Older Adults
• Intervention / Treatment: Behavioral: Exergaming

Detailed Description

Objective To explore the effects of the chair-bound exergaming on the enjoyment of physical activity in in pre-frail/ frail nursing home residents.

To evaluate the effects of the chair-bound exergaming in improving physical and cognitive function in pre-frail/ frail nursing home residents.

Research plan and methodology Thirty nursing home residents will be recruited from the nursing homes.

All the eligible participant will be randomly allocated to either one of the following 2 groups (i) Exergaming (intervention group), or (ii) wait list control.

1. Intervention group (exergaming group, ERG) Those allocated to the ERG will receive supervised chair-bound exercise programme for 12 weeks.
2. Control group (wait list control, CG) Those allocated to the CG will receive supervised chair-bound exercise programme for 12 weeks after post-assessment.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Bonny YM Wong; Phone Number: +852 3970-2976; Email: bymwong@hkmu.edu.hk

Study Locations

• Hong Kong
  • Kowloon, Hong Kong
    • Recruiting
    • Hiu Kwong (Tak Yue) Nursing Centre
    • Contact: Leung; Phone Number: 2367 8918

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• older adults aged 60 years or older living in the nursing homes;
• pre-frail or frail according to the Fried Frailty Phenotypes;
• ability to understand and execute instructions; and
• ability to sit unassisted on a chair or in a wheelchair.

Exclusion Criteria:

• no controlled medical diagnosed of severe cardiometabolic, respiratory and musculoskeletal disorders;
• any conditions that hinder the participation of intervention and assessment; and
• being involved in any other clinical trials.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Wait-list Control; Wait list control, after post-test, 12 week supervised exercise intervention
Experimental: Exergaming; 12-week exergaming intervention	Behavioral: Exergaming; This intervention will last 12 weeks. Frail/ pre-frail participants will engage in supervised chair-bound exergaming.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
upper extremity endurance	upper extremity endurance measured by arm curl test	T0: baseline
upper extremity endurance	upper extremity endurance measured by arm curl test	T1: 6 week
upper extremity endurance	upper extremity endurance measured by arm curl test	T2: immediately (1 week) after intervention
enjoyment	enjoyment of physical activity measured by Physical Activity Enjoyment Scale (PACES)	T0: baseline
enjoyment	enjoyment of physical activity measured by Physical Activity Enjoyment Scale (PACES)	T1: 6 week
enjoyment	enjoyment of physical activity measured by Physical Activity Enjoyment Scale (PACES)	T2: immediately (1 week) after intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
upper extremity strength	upper extremity strength measured by handheld dynamometer	T0: baseline
lung capacity	lung capacity measured by peak flow meter	T0: baseline
sitting balance	sitting balance measured by sitting with opened eyes, sitting with closed eyes, sitting with shaking "no" and sitting with lifted leg	T0: baseline
mental health	mental health measured by Patient Health Questionnaire-4 (PHQ-4), range: 0-12; higher score indicates more psychological distress	T0: baseline
cognitive function	cognitive function measured by Montreal Cognitive Assessment (MoCA), range: 0-30; lower score indicates more cognitive impairment.	T0: baseline
upper extremity strength	upper extremity strength measured by handheld dynamometer	T1: 6 week
upper extremity strength	upper extremity strength measured by handheld dynamometer	T2: immediately (1 week) after intervention
lung capacity	lung capacity measured by peak flow meter	T1: 6 week
lung capacity	lung capacity measured by peak flow meter	T2: immediately (1 week) after intervention
sitting balance	sitting balance measured by sitting with opened eyes, sitting with closed eyes, sitting with shaking "no" and sitting with lifted leg	T1: 6 week
sitting balance	sitting balance measured by sitting with opened eyes, sitting with closed eyes, sitting with shaking "no" and sitting with lifted leg	T2: immediately (1 week) after intervention
feasibility, acceptability and appropriateness of intervention	feasibility, acceptability and appropriateness of intervention measured by questionnaire	T2: immediately (1 week) after intervention
mental health	mental health measured by Patient Health Questionnaire-4 (PHQ-4), range: 0-12; higher score indicates more psychological distress	T1: 6 week
mental health	mental health measured by Patient Health Questionnaire-4 (PHQ-4), range: 0-12; higher score indicates more psychological distress	T2: immediately (1 week) after intervention
cognitive function	cognitive function measured by Montreal Cognitive Assessment (MoCA), range: 0-30; lower score indicates more cognitive impairment.	T1: 6 week
cognitive function	cognitive function measured by Montreal Cognitive Assessment (MoCA), range: 0-30; lower score indicates more cognitive impairment.	T2: immediately (1 week) after intervention

Collaborators and Investigators

• Sponsor: Hong Kong Metropolitan University

Study record dates

Study Major Dates

• Study Start (Actual): April 7, 2025
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: January 16, 2025
• First Submitted That Met QC Criteria: February 25, 2025
• First Posted (Actual): February 27, 2025

Study Record Updates

• Last Update Posted (Actual): May 14, 2025
• Last Update Submitted That Met QC Criteria: May 9, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Frailty
• Other Study ID Numbers: HE-SF2024/58

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No